Chapel Hill Project

Chapel Hill Pharmaceuticals was a biotechnology company focused on the development of targeted delivery systems for therapeutic agents, primarily utilizing nanoparticle technology. Founded by Dr. Leaf Huang, a pioneer in the field of non-viral gene delivery, the company leveraged the LPD (Liposome-Polycation-DNA) platform to enhance the efficacy and safety of oncology treatments. The technology was designed to deliver genetic material or small molecules specifically to tumor cells while minimizing systemic toxicity. Although the company advanced several pre-clinical programs, it is no longer active in its original form, with its foundational technologies continuing to influence academic research and subsequent delivery-focused ventures.